Trials / Terminated
TerminatedNCT05351554
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Kinevant Sciences GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.
Detailed description
Study was terminated after a single participant had received 2 doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Namilumab | Specified dose on specified days |
Timeline
- Start date
- 2022-08-23
- Primary completion
- 2022-11-15
- Completion
- 2022-12-13
- First posted
- 2022-04-28
- Last updated
- 2025-04-17
- Results posted
- 2025-04-17
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05351554. Inclusion in this directory is not an endorsement.